PMID- 35436270
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20221207
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 50
IP  - 296
DP  - 2022 Apr 19
TI  - Prediction factors for the risk of diffuse non-toxic goiter development in type 2 
      diabetic patients.
PG  - 94-98
AB  - Type 2 diabetes mellitus (T2DM) patient outcomes, treatment options, and 
      corresponding healthcare expenses are affected by the presence of different 
      comorbidities. AIM: The aim of this work was to develop an algorithm for 
      predicting the risk of diffuse non-toxic goitre development in patients with T2DM 
      according to a mathematical model obtained by regression analysis, for the timely 
      implementation of appropriate preventive measures among T2DM patients. MATERIALS 
      AND METHODS: We analyzed 541 medical records of T2DM patients. RESULTS: It was 
      found the following risk factors influencing the occurrence of diffuse non-toxic 
      goitre in patients with T2DM: age, gender, body mass index (BMI), glycosylated 
      hemoglobin (HbA1c), homeostasis model assessment for insulin resistance 
      (HOMA-IR), thyroid stimulating hormone (TSH), free thyroxine (fT4). Prognostic 
      model of the risk of diffuse non-toxic goitre development in T2DM patients was 
      built using multiple regression analysis. In order to stratify the risk of 
      diffuse nontoxic goitre development in T2DM patients, the following criteria were 
      proposed: no risk at RCG </= 5.0; low risk at 5.1</= RCG </=12,9; high risk at RCG 
      >/=13.0.; where RCG - risk coefficient for the diffuse non-toxic goiter development 
      in T2DM patients. CONCLUSIONS: Therefore, the developed algorithm and 
      mathematical model for predicting the development of diffuse non-toxic goitre in 
      T2DM patients are highly informative and allow to determine in advance the 
      contingent of patients with a high probability of diffuse non-toxic goitre risk 
      based both on routine laboratory data, such as HbA1c, HOMA-IR, TSH, fT4 levels 
      and such factors as age, gender, and BMI.
CI  - (c) 2022 MEDPRESS.
FAU - Musiienko, Volodymyr
AU  - Musiienko V
AD  - Department of Functional and Laboratory Diagnostics, I Horbachevsky Ternopil 
      National Medical University, Ternopil, Ukraine.
FAU - Sverstiuk, Andriy
AU  - Sverstiuk A
AD  - Department of Medical Informatics, I Horbachevsky Ternopil National Medical 
      University, Ternopil, Ukraine.
FAU - Lepyavko, Andriy
AU  - Lepyavko A
AD  - Department of Internal Medicine N2, I Horbachevsky Ternopil National Medical 
      University, Ternopil, Ukraine.
FAU - Mazur, Lyudmyla
AU  - Mazur L
AD  - Department of Higher Nursing Education, Patient Care and Clinical Immunology, I 
      Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
FAU - Danchak, Svitlana
AU  - Danchak S
AD  - Department of Higher Nursing Education, Patient Care and Clinical Immunology, I 
      Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
FAU - Lisnianska, Natalia
AU  - Lisnianska N
AD  - Department of Pathologic Physiology, Bukovinian State Medical University, 
      Chernivtsi, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - 0 (Glycated Hemoglobin A)
RN  - 9002-71-5 (Thyrotropin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Glycated Hemoglobin/analysis
MH  - *Goiter
MH  - Humans
MH  - *Insulin Resistance
MH  - Thyroid Function Tests
MH  - Thyrotropin
OTO - NOTNLM
OT  - diffuse non-toxic goiter
OT  - mathematical model
OT  - risk
OT  - type 2 diabetes mellitus
EDAT- 2022/04/19 06:00
MHDA- 2022/04/21 06:00
CRDT- 2022/04/18 17:10
PHST- 2022/04/18 17:10 [entrez]
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
AID - PML296-094 [pii]
PST - ppublish
SO  - Pol Merkur Lekarski. 2022 Apr 19;50(296):94-98.